Abstract
Ebselen, N-phenyl-1,2-benzoisoselenazol-3(2H)-one, an established anti-oxidant and cytoprotective agent, has been assessed for an array of pharmaceutical applications in treating a multitude of disorders and maladies. It has further been identified as an anti-microbial and anti-viral agent against multiple infectious agents and has even been FDA-approved for a variety of these applications. While ebselen has captured pharmaceutical interest, its tellurium analogue, ebtellur, has yet to be successfully obtained, and in only one case was an attempt to obtain ebtellur reported. We have developed multiple new synthetic routes specifically targeting the first synthesis of ebtellur and discuss the viability of each pathway herein.
College
College of Science & Engineering
Department
Chemistry
First Advisor/Mentor
Joseph West, Ph.D.
Start Date
4-19-2023 2:00 PM
End Date
4-19-2023 3:00 PM
Presentation Type
Poster Session
Format of Presentation or Performance
In-Person
Session
2b=2pm-3pm
Poster Number
14
Included in
Development of New Synthetic Routes for Ebselen in Pursuit of the First Synthesis of Ebtellur
Ebselen, N-phenyl-1,2-benzoisoselenazol-3(2H)-one, an established anti-oxidant and cytoprotective agent, has been assessed for an array of pharmaceutical applications in treating a multitude of disorders and maladies. It has further been identified as an anti-microbial and anti-viral agent against multiple infectious agents and has even been FDA-approved for a variety of these applications. While ebselen has captured pharmaceutical interest, its tellurium analogue, ebtellur, has yet to be successfully obtained, and in only one case was an attempt to obtain ebtellur reported. We have developed multiple new synthetic routes specifically targeting the first synthesis of ebtellur and discuss the viability of each pathway herein.
